Key result
Endothelial dysfunction, characterized by reduced nitric oxide bioavailability and eNOS uncoupling, contributes to the pathogenesis and worsening of cardiovascular and endocrine-metabolic diseases.
Endothelial dysfunction, driven by mechanisms such as reduced nitric oxide bioavailability and eNOS uncoupling, plays a critical role in the pathogenesis and progression of cardiovascular and endocrine-metabolic diseases.
Answers are grounded in this paper and cite their sources.
Supports endothelial dysfunction as therapeutic target; leaves open interventional trials before clinical adoption.
The endothelium plays a vital role in maintaining circulatory homeostasis by the release of relaxing and contracting factors. Any change in this balance may result in a process known as endothelial dysfunction that leads to impaired control of vascular tone and contributes to the pathogenesis of some cardiovascular and endocrine/metabolic diseases. Reduced endothelium-derived nitric oxide (NO) bioavailability and increased production of thromboxane A2, prostaglandin H2 and superoxide anion in conductance and resistance arteries are commonly associated with endothelial dysfunction in hypertensive, diabetic and obese animals, resulting in reduced endothelium-dependent vasodilatation and in increased vasoconstrictor responses. In addition, recent studies have demonstrated the role of enhanced overactivation of β-adrenergic receptors inducing vascular cytokine production and endothelial NO synthase (eNOS) uncoupling that seem to be the mechanisms underlying endothelial dysfunction in hypertension, heart failure and in endocrine-metabolic disorders. However, some adaptive mechanisms can occur in the initial stages of hypertension, such as increased NO production by eNOS. The present review focuses on the role of NO bioavailability, eNOS uncoupling, cyclooxygenase-derived products and pro-inflammatory factors on the endothelial dysfunction that occurs in hypertension, sympathetic hyperactivity, diabetes mellitus, and obesity. These are cardiovascular and endocrine-metabolic diseases of high incidence and mortality around the world, especially in developing countries and endothelial dysfunction contributes to triggering, maintenance and worsening of these pathological situations.
No takes yet. Share an insight, caveat, or question.
Davel et al. (2011) conducted a review in Cardiovascular and endocrine-metabolic diseases. Endothelial dysfunction was evaluated. Endothelial dysfunction, characterized by reduced nitric oxide bioavailability and eNOS uncoupling, contributes to the pathogenesis and worsening of cardiovascular and endocrine-metabolic diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: